Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. has strategic collaborations with Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas; and NVIDIA designed to harness DGX SuperPODs. The company was incorporated in 1990 and is headquartered in New York, New York.
Kontrakty CFD to złożone instrumenty, które wiążą się z dużym ryzykiem gwałtownej straty środków na skutek zastosowania dźwigni finansowej. 76% inwestorów detalicznych odnotowuje straty w handlu kontraktami CFD z tym dostawcą. Powinieneś rozważyć, czy rozumiesz, jak działają kontrakty CFD i czy możesz sobie pozwolić na podjęcie wysokiego ryzyka utraty pieniędzy. Prosimy o zapoznanie się z naszym Oświadczeniem o ryzyku
Oceny i recenzje
Oceny i recenzje
